Payment overview · 2025
General Payments
$288.05
12 reported records · 6 companies
Healthcare provider profile · identity verified
Anthony T Bernens, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WALNUT CREEK, CA · NPI 1215983440
Verified facts
What the public records show
CMS Open Payments records show Anthony T Bernens, MD received $288.05 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.89 | 33.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.66 | 24.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.66 | 13.1% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $29.89 | 10.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.55 | 9.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.40 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.05 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.14 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.66 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 44 |
| Losartan Potassium | Losartan Potassium | 147 | 41 |
| Famotidine | Famotidine | 131 | 34 |
| Gabapentin | Gabapentin | 119 | 28 |
| Simvastatin | Simvastatin | 116 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 34 |
| Eliquis | Apixaban | 109 | 27 |
| Allopurinol | Allopurinol | 104 | 25 |
| Omeprazole | Omeprazole | 100 | 26 |
| Sertraline Hcl | Sertraline Hcl | 82 | 18 |
| Lisinopril | Lisinopril | 77 | 21 |
| Trazodone Hcl | Trazodone Hcl | 76 | 21 |
| Lorazepam | Lorazepam | 68 | 18 |
| Celecoxib | Celecoxib | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 30 |
| Paxlovid | Nirmatrelvir/Ritonavir | 56 | 48 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 18 |
| Potassium Chloride | Potassium Chloride | 53 | 14 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Prednisone | Prednisone | 44 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Folic Acid | Folic Acid | 42 | 13 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 11 |
| Azithromycin | Azithromycin | 34 | 26 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Baclofen | Baclofen | 32 | 14 |
| Cephalexin | Cephalexin | 32 | 22 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 11 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Zaleplon | Zaleplon | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.05 · 12 records | Exact Sciences Corporation | CRYSVITA, Cologuard Collection Kit, EVENITY, FASENRA, QULIPTA, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error